Drug Development | Novartis

Press Release
Aug 18, 2025

New Novartis ESC data highlights strength of cardiovascular portfolio
Press Release
Jul 29, 2024

Novartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML
Press Release
Dec 30, 2024

Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
Press Release
Feb 28, 2025

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
Story
Apr 08, 2024

Drug delivery, service delivery, and the future of cancer care
Press Release
Dec 06, 2023

Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
Story
Dec 12, 2023

Innovation fueled by compassion
Story
Dec 08, 2023

Shoulder to shoulder
Press Release
Nov 20, 2023

Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
Story
Sep 08, 2023

Treatments for blood cancers and serious blood disorders are advancing rapidly – Novartis is helping lead the way
Story
Nov 01, 2022

A scientist from the start – Q&A with NIBR President Fiona Marshall
Story
Jun 23, 2022

Renewing our commitment to neglected tropical disease and malaria elimination